Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study
Owen, E. C.; Moulder, R. G.; Morse, J. L.; Ainsworth, M. C.; Fabry, A.; Merner, A. R.
Show abstract
Objective: Evaluate differences in side effects between a low and standard dose compounded semaglutide paired with a behavioral companion in the first 16 weeks of treatment using a real-world, retrospective cohort. Methods: Side effects were compared between the low dose protocol (Noom Microdose GLP-1 Rx Program; NMGP, up to 0.6mg/weekly compounded semaglutide) and Noom's standard dose of compounded semaglutide (Noom GLP-1 Rx Program; NGP, up to 1.2mg/weekly). Users were propensity score matched on side effect rate in the first 8 weeks when dosing protocols were identical, and longitudinal side effect trajectories were compared via logistic regression. Analyses were conducted on a second cohort with additional matched baseline characteristics. Results: The full sample included 7,682 NGP and 2,877 NMGP users. NMGP users had 34% lower and 29% lower relative odds of reporting GI side effects (p=0.001) and any side effects (p=0.001) by week 16, respectively (n=2,481 per group). Results of the second cohort demonstrated 38% lower odds of any side effect by week 16 among NMGP users (n=958 per group, p=0.019). Conclusions: Lower doses of compounded semaglutide alongside a behavioral companion are associated with fewer side effects in the first 16 weeks compared to a higher dose program.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- MTXPK.org: A clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase 91%
- DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19 90%
- A user-driven framework for dose selection in pregnancy: proof-of-concept for sertraline 90%
Similar papers in this journal
- Preclinical Efficacy in Investigator’s Brochures: Stakeholders’ views on measures to improve Completeness and Robustness 90%
- Trends in analgesia prescribing in primary care in Ireland and England between 2014 and 2022 - a repeated cross-sectional study 90%
- People exposed to proton pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nation-wide matched cohort study 89%
Similar papers in this journal
- Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs 90%
- A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese non-human primate model 90%
- A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes 88%
Similar papers in this journal
- Health Information Exchanges (HIEs) as Novel Sources for Population-Based Post Marketing Surveillance of Medical Products: A Pilot Study from the FDA Sentinel Innovation Center 91%
- Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary 91%
- Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media 90%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.